Association of S100A8/A9 with Lipid-Rich Necrotic Core and Treatment with Biologic Therapy in Patients with Psoriasis: Results from an Observational Cohort Study
Psoriasis is a systemic inflammatory disease with an increased risk of atherosclerotic events and premature cardiovascular disease. S100A7, A8/A9, and A12 are protein complexes that are produced by activated neutrophils, monocytes, and keratinocytes in psoriasis. Lipid-rich necrotic core (LRNC) is a...
Gespeichert in:
| Veröffentlicht in: | Journal of investigative dermatology 2022-11, Vol.142 (11), p.2909-2919 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2919 |
|---|---|
| container_issue | 11 |
| container_start_page | 2909 |
| container_title | Journal of investigative dermatology |
| container_volume | 142 |
| creator | Berg, Alexander R. Hong, Christin G. Svirydava, Maryia Li, Haiou Parel, Philip M. Florida, Elizabeth O’Hagan, Ross Pantoja, Carla J. Lateef, Sundus S. Anzenberg, Paula Harrington, Charlotte L. Ward, Grace Zhou, Wunan Sorokin, Alexander V. Chen, Marcus Y. Teague, Heather L. Buckler, Andrew J. Playford, Martin P. Gelfand, Joel M. Mehta, Nehal N. |
| description | Psoriasis is a systemic inflammatory disease with an increased risk of atherosclerotic events and premature cardiovascular disease. S100A7, A8/A9, and A12 are protein complexes that are produced by activated neutrophils, monocytes, and keratinocytes in psoriasis. Lipid-rich necrotic core (LRNC) is a high-risk coronary plaque feature previously found to be associated with cardiovascular risk factors and psoriasis severity. LRNC can decrease with biologic therapy, but how this occurs remains unknown. We investigated the relationship between S100 proteins, LRNC, and biologic therapy in psoriasis. S100A8/A9 associated with LRNC in fully adjusted models (β = 0.27, P = 0.009; n = 125 patients with psoriasis with available coronary computed tomography angiography scans; LRNC analyses; and serum S100A7, S100A8, S100A9, S100A12, and S100A8/A9 levels). At 1 year, in patients receiving biologic therapy (36 of 73 patients had 1-year coronary computed tomography angiography scans available), a 79% reduction in S100A8/A9 levels (‒172 [‒291.7 to 26.4] vs. ‒29.9 [‒137.9 to 50.5]; P = 0.04) and a 0.6 mm2 reduction in average LRNC area (0.04 [‒0.48 to 0.77] vs. ‒0.56 [‒1.8 to 0.13]; P = 0.02) were noted. These results highlight the potential role of S100A8/A9 in the development of high-risk coronary plaque in psoriasis.
[Display omitted] |
| doi_str_mv | 10.1016/j.jid.2022.05.1085 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2681044795</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022202X22015275</els_id><sourcerecordid>2681044795</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-decccf3ac45cfe0c71f613457f7b76253df6ef96cf76dc07d9ffe5ba4cc39c7c3</originalsourceid><addsrcrecordid>eNp9kcFuEzEQhi0EoqHwAhyQj1w2tXfX6yziEqIClSJatUHiZjnjMXG0uw62t1UehzfFYVuOnEaa-f5_7PkJecvZnDPeXOzne2fmJSvLORO5tRDPyIyLsiq4rOVzMmN5VOT5jzPyKsY9y6JaLF6Ss0pIwXjdzsjvZYwenE7OD9RbescZWy4uli19cGlH1-7gTHHrYEe_IQSfHNCVD0j1YOgmoE49DmliPznf-Z8Z2Oww6MORuoHeZOMMxIm4iT44HV38QG8xjl3u2-D7bEavtxHD_d9n6C6v2PmQ6F0azfE1eWF1F_HNYz0n3z9fblZfi_X1l6vVcl1AzVgqDAKArTTUAiwykNw2vKqFtHIrm1JUxjZo2wasbAwwaVprUWx1DVC1IKE6J-8n30Pwv0aMSfUuAnadHtCPUZXNgrO6lq3IaDmh-SIxBrTqEFyvw1Fxpk7RqL3K0ahTNIoJdYomi949-o_bHs0_yVMWGfg4AZh_ee8wqAj5eIDGBYSkjHf_8_8DP0OiDg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2681044795</pqid></control><display><type>article</type><title>Association of S100A8/A9 with Lipid-Rich Necrotic Core and Treatment with Biologic Therapy in Patients with Psoriasis: Results from an Observational Cohort Study</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Berg, Alexander R. ; Hong, Christin G. ; Svirydava, Maryia ; Li, Haiou ; Parel, Philip M. ; Florida, Elizabeth ; O’Hagan, Ross ; Pantoja, Carla J. ; Lateef, Sundus S. ; Anzenberg, Paula ; Harrington, Charlotte L. ; Ward, Grace ; Zhou, Wunan ; Sorokin, Alexander V. ; Chen, Marcus Y. ; Teague, Heather L. ; Buckler, Andrew J. ; Playford, Martin P. ; Gelfand, Joel M. ; Mehta, Nehal N.</creator><creatorcontrib>Berg, Alexander R. ; Hong, Christin G. ; Svirydava, Maryia ; Li, Haiou ; Parel, Philip M. ; Florida, Elizabeth ; O’Hagan, Ross ; Pantoja, Carla J. ; Lateef, Sundus S. ; Anzenberg, Paula ; Harrington, Charlotte L. ; Ward, Grace ; Zhou, Wunan ; Sorokin, Alexander V. ; Chen, Marcus Y. ; Teague, Heather L. ; Buckler, Andrew J. ; Playford, Martin P. ; Gelfand, Joel M. ; Mehta, Nehal N.</creatorcontrib><description>Psoriasis is a systemic inflammatory disease with an increased risk of atherosclerotic events and premature cardiovascular disease. S100A7, A8/A9, and A12 are protein complexes that are produced by activated neutrophils, monocytes, and keratinocytes in psoriasis. Lipid-rich necrotic core (LRNC) is a high-risk coronary plaque feature previously found to be associated with cardiovascular risk factors and psoriasis severity. LRNC can decrease with biologic therapy, but how this occurs remains unknown. We investigated the relationship between S100 proteins, LRNC, and biologic therapy in psoriasis. S100A8/A9 associated with LRNC in fully adjusted models (β = 0.27, P = 0.009; n = 125 patients with psoriasis with available coronary computed tomography angiography scans; LRNC analyses; and serum S100A7, S100A8, S100A9, S100A12, and S100A8/A9 levels). At 1 year, in patients receiving biologic therapy (36 of 73 patients had 1-year coronary computed tomography angiography scans available), a 79% reduction in S100A8/A9 levels (‒172 [‒291.7 to 26.4] vs. ‒29.9 [‒137.9 to 50.5]; P = 0.04) and a 0.6 mm2 reduction in average LRNC area (0.04 [‒0.48 to 0.77] vs. ‒0.56 [‒1.8 to 0.13]; P = 0.02) were noted. These results highlight the potential role of S100A8/A9 in the development of high-risk coronary plaque in psoriasis.
[Display omitted]</description><identifier>ISSN: 0022-202X</identifier><identifier>EISSN: 1523-1747</identifier><identifier>DOI: 10.1016/j.jid.2022.05.1085</identifier><identifier>PMID: 35750149</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Biological Therapy ; Biomarkers ; Calgranulin A ; Calgranulin B ; Cohort Studies ; Humans ; Lipids ; Necrosis ; Psoriasis - drug therapy ; Psoriasis - metabolism ; S100 Proteins ; S100A12 Protein</subject><ispartof>Journal of investigative dermatology, 2022-11, Vol.142 (11), p.2909-2919</ispartof><rights>2022 The Authors</rights><rights>Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-decccf3ac45cfe0c71f613457f7b76253df6ef96cf76dc07d9ffe5ba4cc39c7c3</citedby><cites>FETCH-LOGICAL-c400t-decccf3ac45cfe0c71f613457f7b76253df6ef96cf76dc07d9ffe5ba4cc39c7c3</cites><orcidid>0000-0001-6913-833X ; 0000-0003-0743-9369 ; 0000-0002-0443-7889 ; 0000-0001-6013-4252 ; 0000-0002-0786-4835 ; 0000-0001-9128-6160 ; 0000-0001-7115-4806 ; 0000-0002-2291-4888 ; 0000-0002-1272-3316 ; 0000-0003-1994-1663 ; 0000-0002-2310-756X ; 0000-0002-5571-7266 ; 0000-0003-4404-7727 ; 0000-0002-8480-0181 ; 0000-0001-5884-5004 ; 0000-0003-3886-3752 ; 0000-0003-4939-5130 ; 0000-0002-9057-1346 ; 0000-0003-3480-2661 ; 0000-0002-9705-0746</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35750149$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berg, Alexander R.</creatorcontrib><creatorcontrib>Hong, Christin G.</creatorcontrib><creatorcontrib>Svirydava, Maryia</creatorcontrib><creatorcontrib>Li, Haiou</creatorcontrib><creatorcontrib>Parel, Philip M.</creatorcontrib><creatorcontrib>Florida, Elizabeth</creatorcontrib><creatorcontrib>O’Hagan, Ross</creatorcontrib><creatorcontrib>Pantoja, Carla J.</creatorcontrib><creatorcontrib>Lateef, Sundus S.</creatorcontrib><creatorcontrib>Anzenberg, Paula</creatorcontrib><creatorcontrib>Harrington, Charlotte L.</creatorcontrib><creatorcontrib>Ward, Grace</creatorcontrib><creatorcontrib>Zhou, Wunan</creatorcontrib><creatorcontrib>Sorokin, Alexander V.</creatorcontrib><creatorcontrib>Chen, Marcus Y.</creatorcontrib><creatorcontrib>Teague, Heather L.</creatorcontrib><creatorcontrib>Buckler, Andrew J.</creatorcontrib><creatorcontrib>Playford, Martin P.</creatorcontrib><creatorcontrib>Gelfand, Joel M.</creatorcontrib><creatorcontrib>Mehta, Nehal N.</creatorcontrib><title>Association of S100A8/A9 with Lipid-Rich Necrotic Core and Treatment with Biologic Therapy in Patients with Psoriasis: Results from an Observational Cohort Study</title><title>Journal of investigative dermatology</title><addtitle>J Invest Dermatol</addtitle><description>Psoriasis is a systemic inflammatory disease with an increased risk of atherosclerotic events and premature cardiovascular disease. S100A7, A8/A9, and A12 are protein complexes that are produced by activated neutrophils, monocytes, and keratinocytes in psoriasis. Lipid-rich necrotic core (LRNC) is a high-risk coronary plaque feature previously found to be associated with cardiovascular risk factors and psoriasis severity. LRNC can decrease with biologic therapy, but how this occurs remains unknown. We investigated the relationship between S100 proteins, LRNC, and biologic therapy in psoriasis. S100A8/A9 associated with LRNC in fully adjusted models (β = 0.27, P = 0.009; n = 125 patients with psoriasis with available coronary computed tomography angiography scans; LRNC analyses; and serum S100A7, S100A8, S100A9, S100A12, and S100A8/A9 levels). At 1 year, in patients receiving biologic therapy (36 of 73 patients had 1-year coronary computed tomography angiography scans available), a 79% reduction in S100A8/A9 levels (‒172 [‒291.7 to 26.4] vs. ‒29.9 [‒137.9 to 50.5]; P = 0.04) and a 0.6 mm2 reduction in average LRNC area (0.04 [‒0.48 to 0.77] vs. ‒0.56 [‒1.8 to 0.13]; P = 0.02) were noted. These results highlight the potential role of S100A8/A9 in the development of high-risk coronary plaque in psoriasis.
[Display omitted]</description><subject>Biological Therapy</subject><subject>Biomarkers</subject><subject>Calgranulin A</subject><subject>Calgranulin B</subject><subject>Cohort Studies</subject><subject>Humans</subject><subject>Lipids</subject><subject>Necrosis</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis - metabolism</subject><subject>S100 Proteins</subject><subject>S100A12 Protein</subject><issn>0022-202X</issn><issn>1523-1747</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFuEzEQhi0EoqHwAhyQj1w2tXfX6yziEqIClSJatUHiZjnjMXG0uw62t1UehzfFYVuOnEaa-f5_7PkJecvZnDPeXOzne2fmJSvLORO5tRDPyIyLsiq4rOVzMmN5VOT5jzPyKsY9y6JaLF6Ss0pIwXjdzsjvZYwenE7OD9RbescZWy4uli19cGlH1-7gTHHrYEe_IQSfHNCVD0j1YOgmoE49DmliPznf-Z8Z2Oww6MORuoHeZOMMxIm4iT44HV38QG8xjl3u2-D7bEavtxHD_d9n6C6v2PmQ6F0azfE1eWF1F_HNYz0n3z9fblZfi_X1l6vVcl1AzVgqDAKArTTUAiwykNw2vKqFtHIrm1JUxjZo2wasbAwwaVprUWx1DVC1IKE6J-8n30Pwv0aMSfUuAnadHtCPUZXNgrO6lq3IaDmh-SIxBrTqEFyvw1Fxpk7RqL3K0ahTNIoJdYomi949-o_bHs0_yVMWGfg4AZh_ee8wqAj5eIDGBYSkjHf_8_8DP0OiDg</recordid><startdate>202211</startdate><enddate>202211</enddate><creator>Berg, Alexander R.</creator><creator>Hong, Christin G.</creator><creator>Svirydava, Maryia</creator><creator>Li, Haiou</creator><creator>Parel, Philip M.</creator><creator>Florida, Elizabeth</creator><creator>O’Hagan, Ross</creator><creator>Pantoja, Carla J.</creator><creator>Lateef, Sundus S.</creator><creator>Anzenberg, Paula</creator><creator>Harrington, Charlotte L.</creator><creator>Ward, Grace</creator><creator>Zhou, Wunan</creator><creator>Sorokin, Alexander V.</creator><creator>Chen, Marcus Y.</creator><creator>Teague, Heather L.</creator><creator>Buckler, Andrew J.</creator><creator>Playford, Martin P.</creator><creator>Gelfand, Joel M.</creator><creator>Mehta, Nehal N.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6913-833X</orcidid><orcidid>https://orcid.org/0000-0003-0743-9369</orcidid><orcidid>https://orcid.org/0000-0002-0443-7889</orcidid><orcidid>https://orcid.org/0000-0001-6013-4252</orcidid><orcidid>https://orcid.org/0000-0002-0786-4835</orcidid><orcidid>https://orcid.org/0000-0001-9128-6160</orcidid><orcidid>https://orcid.org/0000-0001-7115-4806</orcidid><orcidid>https://orcid.org/0000-0002-2291-4888</orcidid><orcidid>https://orcid.org/0000-0002-1272-3316</orcidid><orcidid>https://orcid.org/0000-0003-1994-1663</orcidid><orcidid>https://orcid.org/0000-0002-2310-756X</orcidid><orcidid>https://orcid.org/0000-0002-5571-7266</orcidid><orcidid>https://orcid.org/0000-0003-4404-7727</orcidid><orcidid>https://orcid.org/0000-0002-8480-0181</orcidid><orcidid>https://orcid.org/0000-0001-5884-5004</orcidid><orcidid>https://orcid.org/0000-0003-3886-3752</orcidid><orcidid>https://orcid.org/0000-0003-4939-5130</orcidid><orcidid>https://orcid.org/0000-0002-9057-1346</orcidid><orcidid>https://orcid.org/0000-0003-3480-2661</orcidid><orcidid>https://orcid.org/0000-0002-9705-0746</orcidid></search><sort><creationdate>202211</creationdate><title>Association of S100A8/A9 with Lipid-Rich Necrotic Core and Treatment with Biologic Therapy in Patients with Psoriasis: Results from an Observational Cohort Study</title><author>Berg, Alexander R. ; Hong, Christin G. ; Svirydava, Maryia ; Li, Haiou ; Parel, Philip M. ; Florida, Elizabeth ; O’Hagan, Ross ; Pantoja, Carla J. ; Lateef, Sundus S. ; Anzenberg, Paula ; Harrington, Charlotte L. ; Ward, Grace ; Zhou, Wunan ; Sorokin, Alexander V. ; Chen, Marcus Y. ; Teague, Heather L. ; Buckler, Andrew J. ; Playford, Martin P. ; Gelfand, Joel M. ; Mehta, Nehal N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-decccf3ac45cfe0c71f613457f7b76253df6ef96cf76dc07d9ffe5ba4cc39c7c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biological Therapy</topic><topic>Biomarkers</topic><topic>Calgranulin A</topic><topic>Calgranulin B</topic><topic>Cohort Studies</topic><topic>Humans</topic><topic>Lipids</topic><topic>Necrosis</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis - metabolism</topic><topic>S100 Proteins</topic><topic>S100A12 Protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berg, Alexander R.</creatorcontrib><creatorcontrib>Hong, Christin G.</creatorcontrib><creatorcontrib>Svirydava, Maryia</creatorcontrib><creatorcontrib>Li, Haiou</creatorcontrib><creatorcontrib>Parel, Philip M.</creatorcontrib><creatorcontrib>Florida, Elizabeth</creatorcontrib><creatorcontrib>O’Hagan, Ross</creatorcontrib><creatorcontrib>Pantoja, Carla J.</creatorcontrib><creatorcontrib>Lateef, Sundus S.</creatorcontrib><creatorcontrib>Anzenberg, Paula</creatorcontrib><creatorcontrib>Harrington, Charlotte L.</creatorcontrib><creatorcontrib>Ward, Grace</creatorcontrib><creatorcontrib>Zhou, Wunan</creatorcontrib><creatorcontrib>Sorokin, Alexander V.</creatorcontrib><creatorcontrib>Chen, Marcus Y.</creatorcontrib><creatorcontrib>Teague, Heather L.</creatorcontrib><creatorcontrib>Buckler, Andrew J.</creatorcontrib><creatorcontrib>Playford, Martin P.</creatorcontrib><creatorcontrib>Gelfand, Joel M.</creatorcontrib><creatorcontrib>Mehta, Nehal N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of investigative dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berg, Alexander R.</au><au>Hong, Christin G.</au><au>Svirydava, Maryia</au><au>Li, Haiou</au><au>Parel, Philip M.</au><au>Florida, Elizabeth</au><au>O’Hagan, Ross</au><au>Pantoja, Carla J.</au><au>Lateef, Sundus S.</au><au>Anzenberg, Paula</au><au>Harrington, Charlotte L.</au><au>Ward, Grace</au><au>Zhou, Wunan</au><au>Sorokin, Alexander V.</au><au>Chen, Marcus Y.</au><au>Teague, Heather L.</au><au>Buckler, Andrew J.</au><au>Playford, Martin P.</au><au>Gelfand, Joel M.</au><au>Mehta, Nehal N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of S100A8/A9 with Lipid-Rich Necrotic Core and Treatment with Biologic Therapy in Patients with Psoriasis: Results from an Observational Cohort Study</atitle><jtitle>Journal of investigative dermatology</jtitle><addtitle>J Invest Dermatol</addtitle><date>2022-11</date><risdate>2022</risdate><volume>142</volume><issue>11</issue><spage>2909</spage><epage>2919</epage><pages>2909-2919</pages><issn>0022-202X</issn><eissn>1523-1747</eissn><abstract>Psoriasis is a systemic inflammatory disease with an increased risk of atherosclerotic events and premature cardiovascular disease. S100A7, A8/A9, and A12 are protein complexes that are produced by activated neutrophils, monocytes, and keratinocytes in psoriasis. Lipid-rich necrotic core (LRNC) is a high-risk coronary plaque feature previously found to be associated with cardiovascular risk factors and psoriasis severity. LRNC can decrease with biologic therapy, but how this occurs remains unknown. We investigated the relationship between S100 proteins, LRNC, and biologic therapy in psoriasis. S100A8/A9 associated with LRNC in fully adjusted models (β = 0.27, P = 0.009; n = 125 patients with psoriasis with available coronary computed tomography angiography scans; LRNC analyses; and serum S100A7, S100A8, S100A9, S100A12, and S100A8/A9 levels). At 1 year, in patients receiving biologic therapy (36 of 73 patients had 1-year coronary computed tomography angiography scans available), a 79% reduction in S100A8/A9 levels (‒172 [‒291.7 to 26.4] vs. ‒29.9 [‒137.9 to 50.5]; P = 0.04) and a 0.6 mm2 reduction in average LRNC area (0.04 [‒0.48 to 0.77] vs. ‒0.56 [‒1.8 to 0.13]; P = 0.02) were noted. These results highlight the potential role of S100A8/A9 in the development of high-risk coronary plaque in psoriasis.
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35750149</pmid><doi>10.1016/j.jid.2022.05.1085</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-6913-833X</orcidid><orcidid>https://orcid.org/0000-0003-0743-9369</orcidid><orcidid>https://orcid.org/0000-0002-0443-7889</orcidid><orcidid>https://orcid.org/0000-0001-6013-4252</orcidid><orcidid>https://orcid.org/0000-0002-0786-4835</orcidid><orcidid>https://orcid.org/0000-0001-9128-6160</orcidid><orcidid>https://orcid.org/0000-0001-7115-4806</orcidid><orcidid>https://orcid.org/0000-0002-2291-4888</orcidid><orcidid>https://orcid.org/0000-0002-1272-3316</orcidid><orcidid>https://orcid.org/0000-0003-1994-1663</orcidid><orcidid>https://orcid.org/0000-0002-2310-756X</orcidid><orcidid>https://orcid.org/0000-0002-5571-7266</orcidid><orcidid>https://orcid.org/0000-0003-4404-7727</orcidid><orcidid>https://orcid.org/0000-0002-8480-0181</orcidid><orcidid>https://orcid.org/0000-0001-5884-5004</orcidid><orcidid>https://orcid.org/0000-0003-3886-3752</orcidid><orcidid>https://orcid.org/0000-0003-4939-5130</orcidid><orcidid>https://orcid.org/0000-0002-9057-1346</orcidid><orcidid>https://orcid.org/0000-0003-3480-2661</orcidid><orcidid>https://orcid.org/0000-0002-9705-0746</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-202X |
| ispartof | Journal of investigative dermatology, 2022-11, Vol.142 (11), p.2909-2919 |
| issn | 0022-202X 1523-1747 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2681044795 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Biological Therapy Biomarkers Calgranulin A Calgranulin B Cohort Studies Humans Lipids Necrosis Psoriasis - drug therapy Psoriasis - metabolism S100 Proteins S100A12 Protein |
| title | Association of S100A8/A9 with Lipid-Rich Necrotic Core and Treatment with Biologic Therapy in Patients with Psoriasis: Results from an Observational Cohort Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T06%3A37%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20S100A8/A9%20with%20Lipid-Rich%20Necrotic%20Core%20and%20Treatment%20with%20Biologic%20Therapy%20in%20Patients%20with%20Psoriasis:%20Results%20from%20an%20Observational%20Cohort%20Study&rft.jtitle=Journal%20of%20investigative%20dermatology&rft.au=Berg,%20Alexander%20R.&rft.date=2022-11&rft.volume=142&rft.issue=11&rft.spage=2909&rft.epage=2919&rft.pages=2909-2919&rft.issn=0022-202X&rft.eissn=1523-1747&rft_id=info:doi/10.1016/j.jid.2022.05.1085&rft_dat=%3Cproquest_cross%3E2681044795%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2681044795&rft_id=info:pmid/35750149&rft_els_id=S0022202X22015275&rfr_iscdi=true |